High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission

Arnold S. Freedman, John G. Gribben, Donna Neuberg, Peter Mauch, Robert J. Soiffer, Kenneth C. Anderson, Lini Pandite, Michael J. Robertson, Mary Kroon, Jerome Ritz, Lee M. Nadler

Research output: Contribution to journalArticle

228 Scopus citations

Abstract

We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow- up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival.

Original languageEnglish (US)
Pages (from-to)2780-2786
Number of pages7
JournalBlood
Volume88
Issue number7
DOIs
StatePublished - Oct 1 1996

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission'. Together they form a unique fingerprint.

  • Cite this

    Freedman, A. S., Gribben, J. G., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K. C., Pandite, L., Robertson, M. J., Kroon, M., Ritz, J., & Nadler, L. M. (1996). High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 88(7), 2780-2786. https://doi.org/10.1182/blood.v88.7.2780.bloodjournal8872780